KirylukK, LiY, Sanna-CherchiS, RohanizadeganM, SuzukiH, EitnerF, et al.: Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet8: 1002765, 2012PubMed
YuGZ, GuoL, DongJF, ShiSF, LiuLJ, WangJW, et al.: Persistent hematuria and kidney disease progression in IgA nephropathy: A cohort study. Am J Kidney Dis76: 90–99, 2020PubMed
MarianiLH, BombackAS, CanettaPA, FlessnerMF, HelmuthM, HladunewichMA, et al.; CureGN Consortium: CureGN study rationale, design, and methods: Establishing a large prospective observational study of glomerular disease. Am J Kidney Dis73: 218–229, 2019PubMed
MarianiLH, BombackAS, CanettaPA, FlessnerMF, HelmuthM, HladunewichMA, ; CureGN Consortium: CureGN study rationale, design, and methods: Establishing a large prospective observational study of glomerular disease. Am J Kidney Dis 73: 218–229, 2019PubMed)| false
SelewskiDT, AmbruzsJM, AppelGB, BombackAS, MatarRB, CaiY, et al.; CureGN Consortium: Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: Findings from the CureGN Study. Kidney Int Rep3: 1373–1384, 2018PubMed
SelewskiDT, AmbruzsJM, AppelGB, BombackAS, MatarRB, CaiY, ; CureGN Consortium: Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: Findings from the CureGN Study. Kidney Int Rep 3: 1373–1384, 2018PubMed)| false
ChenS, TangZ, XiangH, LiX, ChenH, ZhangH, et al.: Etiology and outcome of crescentic glomerulonephritis from a single center in China: A 10-year review. Am J Kidney Dis67: 376–383, 2016PubMed
ChenS, TangZ, XiangH, LiX, ChenH, ZhangH, : Etiology and outcome of crescentic glomerulonephritis from a single center in China: A 10-year review. Am J Kidney Dis 67: 376–383, 2016PubMed)| false
BellurSS, LepeytreF, VorobyevaO, TroyanovS, CookHT, RobertsIS; International IgA Nephropathy Working Group: Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int91: 235–243, 2017PubMed
BellurSS, LepeytreF, VorobyevaO, TroyanovS, CookHT, RobertsIS; International IgA Nephropathy Working Group: Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int 91: 235–243, 2017PubMed)| false
CattranDC, CoppoR, CookHT, FeehallyJ, RobertsIS, TroyanovS, et al.; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int76: 534–545, 2009PubMed
CattranDC, CoppoR, CookHT, FeehallyJ, RobertsIS, TroyanovS, ; Working Group of the International IgA Nephropathy Network and the Renal Pathology Society: The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 76: 534–545, 2009PubMed)| false
TrimarchiH, BarrattJ, CattranDC, CookHT, CoppoR, HaasM, et al.; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants: Oxford Classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int91: 1014–1021, 2017PubMed
TrimarchiH, BarrattJ, CattranDC, CookHT, CoppoR, HaasM, ; IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Conference Participants: Oxford Classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int 91: 1014–1021, 2017PubMed)| false
SatoskarAA, SuleimanS, AyoubI, HemmingerJ, ParikhS, BrodskySV, et al.: Staphylococcus infection-associated GN: Spectrum of IgA staining and prevalence of ANCA in a single-center cohort. Clin J Am Soc Nephrol12: 39–49, 2017PubMed
SatoskarAA, SuleimanS, AyoubI, HemmingerJ, ParikhS, BrodskySV, : Staphylococcus infection-associated GN: Spectrum of IgA staining and prevalence of ANCA in a single-center cohort. Clin J Am Soc Nephrol 12: 39–49, 2017PubMed)| false
BrodskySV, NadasdyT, CassolC, SatoskarA: IgA staining patterns differentiate between IgA nephropathy and IgA-dominant infection-associated glomerulonephritis. Kidney Int Rep5: 909–911, 2020PubMed
BrodskySV, NadasdyT, CassolC, SatoskarA: IgA staining patterns differentiate between IgA nephropathy and IgA-dominant infection-associated glomerulonephritis. Kidney Int Rep 5: 909–911, 2020PubMed)| false
GharaviAG, MoldoveanuZ, WyattRJ, BarkerCV, WoodfordSY, LiftonRP, et al.: Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol19: 1008–1014, 2008PubMed
GaleDP, MolyneuxK, WimburyD, HigginsP, LevineAP, CaplinB, et al.: Galactosylation of IgA1 is associated with common variation in C1GALT1.J Am Soc Nephrol28: 2158–2166, 2017PubMed
GaleDP, MolyneuxK, WimburyD, HigginsP, LevineAP, CaplinB, : Galactosylation of IgA1 is associated with common variation in C1GALT1.J Am Soc Nephrol 28: 2158–2166, 2017PubMed)| false
KirylukK, LiY, ScolariF, Sanna-CherchiS, ChoiM, VerbitskyM, et al.: Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet46: 1187–1196, 2014PubMed
KirylukK, LiY, ScolariF, Sanna-CherchiS, ChoiM, VerbitskyM, : Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46: 1187–1196, 2014PubMed)| false
ThompsonA, CarrollK, A InkerL, FloegeJ, PerkovicV, Boyer-SuavetS, et al.: Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol14: 469–481, 2019PubMed
ThompsonA, CarrollK, A InkerL, FloegeJ, PerkovicV, Boyer-SuavetS, : Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol 14: 469–481, 2019PubMed)| false
BobartSA, AlexanderMP, ShawwaK, VaughanLE, GhamrawiR, SethiS, et al.: The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant36: 840–847, 2021PubMed
BobartSA, AlexanderMP, ShawwaK, VaughanLE, GhamrawiR, SethiS, : The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy. Nephrol Dial Transplant 36: 840–847, 2021PubMed)| false
SimJJ, BhandariSK, BatechM, HeverA, HarrisonTN, ShuYH, et al.: End-stage renal disease and mortality outcomes across different glomerulonephropathies in a large diverse US population. Mayo Clin Proc93: 167–178, 2018PubMed
SimJJ, BhandariSK, BatechM, HeverA, HarrisonTN, ShuYH, : End-stage renal disease and mortality outcomes across different glomerulonephropathies in a large diverse US population. Mayo Clin Proc 93: 167–178, 2018PubMed)| false
BarbourSJ, CoppoR, ZhangH, LiuZH, SuzukiY, MatsuzakiK, et al.; International IgA Nephropathy Network: Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med179: 942–952, 2019PubMed
BarbourSJ, CoppoR, ZhangH, LiuZH, SuzukiY, MatsuzakiK, ; International IgA Nephropathy Network: Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 179: 942–952, 2019PubMed)| false
BarbourSJ, CoppoR, ZhangH, LiuZH, SuzukiY, MatsuzakiK, et al.; International IgA Nephropathy Network: Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney Int102: 160–172, 2022PubMed
BarbourSJ, CoppoR, ZhangH, LiuZH, SuzukiY, MatsuzakiK, ; International IgA Nephropathy Network: Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney Int 102: 160–172, 2022PubMed)| false
RovinBH, AdlerSG, BarrattJ, BridouxF, BurdgeKA, ChanTM, et al.: Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int100: 753–779, 2021PubMed
RovinBH, AdlerSG, BarrattJ, BridouxF, BurdgeKA, ChanTM, : Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100: 753–779, 2021PubMed)| false
CoppoR, D’ArrigoG, TripepiG, RussoML, RobertsISD, BellurS, et al.; ERA-EDTA Immunonephrology Working Group: Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrol Dial Transplant35: 1002–1009, 2020PubMed
CoppoR, D’ArrigoG, TripepiG, RussoML, RobertsISD, BellurS, ; ERA-EDTA Immunonephrology Working Group: Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. Nephrol Dial Transplant 35: 1002–1009, 2020PubMed)| false
JarrickS, LundbergS, WelanderA, CarreroJJ, HöijerJ, BottaiM, et al.: Mortality in IgA nephropathy: A nationwide population-based cohort study. J Am Soc Nephrol30: 866–876, 2019PubMed
PragaM, GutiérrezE, GonzálezE, MoralesE, HernándezE: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol14: 1578–1583, 2003PubMed
PragaM, GutiérrezE, GonzálezE, MoralesE, HernándezE: Treatment of IgA nephropathy with ACE inhibitors: A randomized and controlled trial. J Am Soc Nephrol 14: 1578–1583, 2003PubMed)| false
Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Available at https://kdigo.org/guidelines/gd/. Accessed November 25, 2022
Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group: KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Available at https://kdigo.org/guidelines/gd/. Accessed November 25, 2022)| false
HiranoK, KawamuraT, TsuboiN, OkonogiH, MiyazakiY, IkedaM, et al.: The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. Clin Exp Nephrol17: 555–562, 2013PubMed
HiranoK, KawamuraT, TsuboiN, OkonogiH, MiyazakiY, IkedaM, : The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. Clin Exp Nephrol 17: 555–562, 2013PubMed)| false
RussoE, VerzolaD, SalvidioG, BoninoB, PicciottoD, DrovandiS, et al.: Long-term blood pressure behavior and progression to end-stage renal disease in patients with immunoglobulin A nephropathy: A single-center observational study in Italy. J Hypertens38: 925–935, 2020PubMed
RussoE, VerzolaD, SalvidioG, BoninoB, PicciottoD, DrovandiS, : Long-term blood pressure behavior and progression to end-stage renal disease in patients with immunoglobulin A nephropathy: A single-center observational study in Italy. J Hypertens 38: 925–935, 2020PubMed)| false
KannoY, OkadaH, SarutaT, SuzukiH: Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: A 3-year follow-up. Clin Nephrol54: 360–365, 2000PubMed
KannoY, OkadaH, SarutaT, SuzukiH: Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: A 3-year follow-up. Clin Nephrol 54: 360–365, 2000PubMed)| false
RauenT, EitnerF, FitznerC, SommererC, ZeierM, OtteB, et al.; STOP-IgAN Investigators: Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med373: 2225–2236, 2015PubMed
RauenT, EitnerF, FitznerC, SommererC, ZeierM, OtteB, ; STOP-IgAN Investigators: Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373: 2225–2236, 2015PubMed)| false
RauenT, WiedS, FitznerC, EitnerF, SommererC, ZeierM, et al.; STOP-IgAN Investigators: After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int98: 1044–1052, 2020PubMed
RauenT, WiedS, FitznerC, EitnerF, SommererC, ZeierM, ; STOP-IgAN Investigators: After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int 98: 1044–1052, 2020PubMed)| false
LvJ, ZhangH, WongMG, JardineMJ, HladunewichM, JhaV, et al.; TESTING Study Group: Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA318: 432–442, 2017PubMed
LvJ, ZhangH, WongMG, JardineMJ, HladunewichM, JhaV, ; TESTING Study Group: Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 318: 432–442, 2017PubMed)| false
LvJ, WongMG, HladunewichMA, JhaV, HooiLS, MonaghanH, et al.; TESTING Study Group: Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA327: 1888–1898, 2022PubMed
LvJ, WongMG, HladunewichMA, JhaV, HooiLS, MonaghanH, ; TESTING Study Group: Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 327: 1888–1898, 2022PubMed)| false
FellströmBC, BarrattJ, CookH, CoppoR, FeehallyJ, de FijterJW, et al.; NEFIGAN Trial Investigators: Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial. Lancet389: 2117–2127, 2017PubMed
ZandL, CanettaP, LafayetteR, AslamN, JanN, SethiS, et al.: An open-label pilot study of adrenocorticotrophic hormone in the treatment of IgA nephropathy at high risk of progression. Kidney Int Rep5: 58–65, 2019PubMed
ZandL, CanettaP, LafayetteR, AslamN, JanN, SethiS, : An open-label pilot study of adrenocorticotrophic hormone in the treatment of IgA nephropathy at high risk of progression. Kidney Int Rep 5: 58–65, 2019PubMed)| false
XiaoweiL, BoW, LiL, PengZ: Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria. Int Urol Nephrol52: 129–136, 2020PubMed
XiaoweiL, BoW, LiL, PengZ: Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria. Int Urol Nephrol 52: 129–136, 2020PubMed)| false
O’ShaughnessyMM, LiuS, Montez-RathME, LenihanCR, LafayetteRA, WinkelmayerWC: Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol28: 632–644, 2017PubMed
O’ShaughnessyMM, LiuS, Montez-RathME, LenihanCR, LafayetteRA, WinkelmayerWC: Kidney transplantation outcomes across GN subtypes in the United States. J Am Soc Nephrol 28: 632–644, 2017PubMed)| false
KousiosA, DuncanN, CharifR, TamFWK, LevyJ, CookHT, et al.: Autologous stem cell transplant for the treatment of type I crystal cryoglobulinemic glomerulonephritis caused by monoclonal gammopathy of renal significance (MGRS). Kidney Int Rep4: 1342–1348, 2019PubMed
KousiosA, DuncanN, CharifR, TamFWK, LevyJ, CookHT, : Autologous stem cell transplant for the treatment of type I crystal cryoglobulinemic glomerulonephritis caused by monoclonal gammopathy of renal significance (MGRS). Kidney Int Rep 4: 1342–1348, 2019PubMed)| false
AvasareRS, CanettaPA, BombackAS, MarasaM, CaliskanY, OzlukY, et al.: Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: A case series. Clin J Am Soc Nephrol13: 406–413, 2018PubMed
AvasareRS, CanettaPA, BombackAS, MarasaM, CaliskanY, OzlukY, : Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: A case series. Clin J Am Soc Nephrol 13: 406–413, 2018PubMed)| false
BombackAS, SantorielloD, AvasareRS, Regunathan-ShenkR, CanettaPA, AhnW, et al.: C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int93: 977–985, 2018PubMed
BombackAS, SantorielloD, AvasareRS, Regunathan-ShenkR, CanettaPA, AhnW, : C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 93: 977–985, 2018PubMed)| false
Medjeral-ThomasN, MalikTH, PatelMP, TothT, CookHT, TomsonC, et al.: A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int85: 933–937, 2014PubMed
Medjeral-ThomasN, MalikTH, PatelMP, TothT, CookHT, TomsonC, : A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. Kidney Int 85: 933–937, 2014PubMed)| false
Caravaca-FontánF, TrujilloH, AlonsoM, Díaz-EncarnaciónM, CabelloV, AricetaG, et al.; C3G Study Group of the Spanish Group for the Study of Glomerular Diseases (GLOSEN): Validation of a histologic scoring index for C3 glomerulopathy. Am J Kidney Dis77: 684–695, 2021PubMed
Caravaca-FontánF, TrujilloH, AlonsoM, Díaz-EncarnaciónM, CabelloV, AricetaG, ; C3G Study Group of the Spanish Group for the Study of Glomerular Diseases (GLOSEN): Validation of a histologic scoring index for C3 glomerulopathy. Am J Kidney Dis 77: 684–695, 2021PubMed)| false
Gomes-AlvesI, Castro-FerreiraI: C3 glomerulonephritis associated with monoclonal gammopathy of renal significance. Acta Med Port 34: 372–377, 2021PubMed)| false
TogarsimalemathSK, SethiSK, DuggalR, Le QuintrecM, JhaP, DanielR, et al.: A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney Int92: 876–887, 2017PubMed
TogarsimalemathSK, SethiSK, DuggalR, Le QuintrecM, JhaP, DanielR, : A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. Kidney Int 92: 876–887, 2017PubMed)| false
WangX, Van Lookeren CampagneM, KatschkeJr.KJ, GullipalliD, MiwaT, UedaY, et al.: Prevention of fatal C3 glomerulopathy by recombinant complement receptor of the Ig superfamily. J Am Soc Nephrol29: 2053–2059, 2018PubMed
WangX, Van Lookeren CampagneM, KatschkeJr.KJ, GullipalliD, MiwaT, UedaY, : Prevention of fatal C3 glomerulopathy by recombinant complement receptor of the Ig superfamily. J Am Soc Nephrol 29: 2053–2059, 2018PubMed)| false
AndeenNK, YangHY, DaiDF, MacCossMJ, SmithKD: DnaJ homolog subfamily B member 9 is a putative autoantigen in fibrillary GN. J Am Soc Nephrol29: 231–239, 2018PubMed
AndeenNK, YangHY, DaiDF, MacCossMJ, SmithKD: DnaJ homolog subfamily B member 9 is a putative autoantigen in fibrillary GN. J Am Soc Nephrol 29: 231–239, 2018PubMed)| false
RavindranA, FervenzaFC, SmithRJH, SethiS: C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int 94: 178–186, 2018PubMed)| false
Le QuintrecM, LapeyraqueAL, LionetA, Sellier-LeclercAL, DelmasY, BaudouinV, et al.: Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis72: 84–92, 2018PubMed
Le QuintrecM, LapeyraqueAL, LionetA, Sellier-LeclercAL, DelmasY, BaudouinV, : Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis 72: 84–92, 2018PubMed)| false
RabascoC, CaveroT, RománE, Rojas-RiveraJ, OleaT, EspinosaM, et al.; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int88: 1153–1160, 2015PubMed
RabascoC, CaveroT, RománE, Rojas-RiveraJ, OleaT, EspinosaM, ; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 88: 1153–1160, 2015PubMed)| false
LeungN, BridouxF, BatumanV, ChaidosA, CockwellP, D’AgatiVD, et al.: The evaluation of monoclonal gammopathy of renal significance: A consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol15: 45–59, 2019PubMed
LeungN, BridouxF, BatumanV, ChaidosA, CockwellP, D’AgatiVD, : The evaluation of monoclonal gammopathy of renal significance: A consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 15: 45–59, 2019PubMed)| false
ZandL, LorenzEC, CosioFG, FervenzaFC, NasrSH, GandhiMJ, et al.: Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol25: 1110–1117, 2014PubMed
Regunathan-ShenkR, AvasareRS, AhnW, CanettaPA, CohenDJ, AppelGB, et al.: Kidney transplantation in C3 glomerulopathy: A case series. Am J Kidney Dis73: 316–323, 2019PubMed
LoiratC, FakhouriF, AricetaG, BesbasN, BitzanM, BjerreA, et al.; HUS International: An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol31: 15–39, 2016PubMed
LoiratC, FakhouriF, AricetaG, BesbasN, BitzanM, BjerreA, ; HUS International: An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31: 15–39, 2016PubMed)| false
ScullyM, CatalandS, CoppoP, de la RubiaJ, FriedmanKD, Kremer HovingaJ, et al.; International Working Group for Thrombotic Thrombocytopenic Purpura: Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost15: 312–322, 2017PubMed
ScullyM, CatalandS, CoppoP, de la RubiaJ, FriedmanKD, Kremer HovingaJ, ; International Working Group for Thrombotic Thrombocytopenic Purpura: Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15: 312–322, 2017PubMed)| false
SalléeM, IsmailK, FakhouriF, Vacher-CoponatH, Moussi-FrancésJ, Frémaux-BacchiV, et al.: Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol14: 3, 2013PubMed
De SerresSA, IsenringP: Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. Nephrol Dial Transplant24: 1048–1050, 2009PubMed
De SerresSA, IsenringP: Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. Nephrol Dial Transplant 24: 1048–1050, 2009PubMed)| false
FakhouriF, VercelC, Frémeaux-BacchiV: Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol7: 2100–2106, 2012PubMed
FakhouriF, VercelC, Frémeaux-BacchiV: Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy. Clin J Am Soc Nephrol 7: 2100–2106, 2012PubMed)| false
FakhouriF, RoumeninaL, ProvotF, SalléeM, CaillardS, CouziL, et al.: Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol21: 859–867, 2010PubMed
GagglM, AignerC, CsukaD, SzilágyiÁ, ProhászkaZ, KainR, et al.: Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J Am Soc Nephrol29: 1020–1029, 2018PubMed
GagglM, AignerC, CsukaD, SzilágyiÁ, ProhászkaZ, KainR, : Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome. J Am Soc Nephrol 29: 1020–1029, 2018PubMed)| false
NorisM, CaprioliJ, BresinE, MossaliC, PianettiG, GambaS, et al.: Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol5: 1844–1859, 2010PubMed
NorisM, CaprioliJ, BresinE, MossaliC, PianettiG, GambaS, : Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5: 1844–1859, 2010PubMed)| false
de JongS, VolokhinaEB, de BreukA, NilssonSC, de JongEK, van der KarNCAJ, et al.: Effect of rare coding variants in the CFI gene on Factor I expression levels. Hum Mol Genet29: 2313–2324, 2020PubMed
de JongS, VolokhinaEB, de BreukA, NilssonSC, de JongEK, van der KarNCAJ, : Effect of rare coding variants in the CFI gene on Factor I expression levels. Hum Mol Genet 29: 2313–2324, 2020PubMed)| false
DuvalA, OlagneJ, CognardN, Gautier VargasG, JolyM, PerrinP, et al.: Pregnancy in a kidney transplant woman under treatment with eculizumab for atypical hemolytic uremic syndrome: Is it safe?Kidney Int Rep4: 733–739, 2019PubMed
DuvalA, OlagneJ, CognardN, Gautier VargasG, JolyM, PerrinP, : Pregnancy in a kidney transplant woman under treatment with eculizumab for atypical hemolytic uremic syndrome: Is it safe?Kidney Int Rep 4: 733–739, 2019PubMed)| false
CheungCK, NettletonKJ, WilliamsML, PageAS, LittlerY, GoodlifeA, et al.: Use of eculizumab during pregnancy in kidney transplant recipients with atypical HUS. Kidney Int Rep4: 1658, 2019PubMed
CheungCK, NettletonKJ, WilliamsML, PageAS, LittlerY, GoodlifeA, : Use of eculizumab during pregnancy in kidney transplant recipients with atypical HUS. Kidney Int Rep 4: 1658, 2019PubMed)| false
FakhouriF, FilaM, HummelA, RibesD, Sellier-LeclercAL, VilleS, et al.: Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: A prospective multicenter study. Blood137: 2438–2449, 2021PubMed
AricetaG, DixonBP, KimSH, KapurG, MauchT, OrtizS, et al.; 312 Study Group: The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int100: 225–237, 2021PubMed
AricetaG, DixonBP, KimSH, KapurG, MauchT, OrtizS, ; 312 Study Group: The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 100: 225–237, 2021PubMed)| false